For many people with leukemia, myelodysplastic syndrome (MDS), and other blood cancers, a stem cell transplant offers the best chance for a cure. However, one of the biggest challenges after transplant is graft-versus-host disease (GVHD), a serious complication in which the donor’s immune cells attack the patient’s healthy tissues.
The U.S. Food and Drug Administration (FDA) has approved Tregzi™ (allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq), the first regulatory T cell-based immunotherapy designed to improve outcomes after a matched donor stem cell transplant. The therapy aims to help rebuild the immune system while reducing the risk of chronic GVHD, a complication that can significantly affect quality of life and long-term survival.
What Is a Stem Cell Transplant?
A hematopoietic stem cell transplant (HSCT) replaces damaged bone marrow with healthy blood-forming stem cells from a donor. It is commonly used to treat blood cancers such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and other high-risk hematologic malignancies.
Before the transplant, patients receive high-dose chemotherapy and sometimes radiation to destroy cancer cells and make room for the donor’s healthy stem cells.
After the transplant, the donor’s immune cells help rebuild the patient’s immune system and can also attack any remaining cancer cells. Unfortunately, these donor immune cells may also attack healthy tissues, leading to graft-versus-host disease.
What Is Graft-Versus-Host Disease?
Graft-versus-host disease (GVHD) occurs when immune cells from the donor recognize the recipient’s body as foreign and begin attacking healthy organs.
Chronic GVHD can develop months after transplantation and may affect the skin, eyes, mouth, liver, lungs, and digestive tract. Symptoms range from mild dryness and skin changes to severe organ damage that can greatly impact daily life. Preventing chronic GVHD has been a major goal of stem cell transplant research for decades.
What Is Tregzi?
Tregzi is a precision-engineered cell therapy created from cells collected from the same matched donor providing the stem cell transplant.
Unlike a traditional stem cell transplant, Tregzi contains three carefully prepared cell populations that are given in sequence:
- Healthy blood-forming stem cells (HSPCs) to rebuild the bone marrow
- Regulatory T cells (Tregs), specialized immune cells that help prevent excessive immune reactions
- Conventional T cells, which help fight infections and remaining cancer cells
The goal is to create a healthier balance in the immune system after transplant, allowing it to attack cancer while reducing harmful inflammation that leads to chronic GVHD.
How Is This Different From a Standard Stem Cell Transplant?
In a conventional transplant, donor stem cells are infused along with a mixture of immune cells, and patients typically receive several medications afterward to reduce the risk of GVHD. With Tregzi, the donor cells are specially selected and engineered before infusion to include a higher proportion of regulatory T cells, which naturally help keep the immune system under control. This approach is designed to reduce complications while still allowing the transplanted immune system to fight cancer effectively.
What Did the Clinical Trial Show?
The FDA approval was based on the Phase 3 Precision-T clinical trial, which enrolled 187 adults with blood cancers undergoing matched donor stem cell transplantation. Researchers compared patients who received Tregzi with those who underwent a standard stem cell transplant.
The results showed important improvements:
- Patients receiving Tregzi were significantly more likely to remain free of chronic graft-versus-host disease.
- At 12 months, only 12.6% of patients treated with Tregzi developed moderate-to-severe chronic GVHD, compared with 44.0% of patients receiving a standard transplant.
- The median duration of chronic GVHD-free survival had not yet been reached in the Tregzi group, compared with 7.3 months in the standard transplant group.
- All patients receiving Tregzi successfully achieved recovery of their white blood cells after transplantation, an important sign that the new bone marrow had begun functioning.
Who May Be Eligible?
Tregzi is approved for adults with hematologic malignancies who:
- Require a matched donor stem cell transplant
- Are receiving a myeloablative conditioning regimen (high-dose chemotherapy before transplant)
- Have a suitable matched donor
Your transplant team can determine whether this therapy is appropriate based on your cancer type, donor availability, and overall health.
What Are the Possible Risks?
Because Tregzi is used during stem cell transplantation, patients remain at risk for transplant-related complications. The prescribing information includes warnings about graft failure, acute or chronic graft-versus-host disease, infusion-related reactions, serious infections, and secondary cancers, including cancers originating from donor cells. Patients receiving Tregzi are closely monitored by their transplant team throughout recovery.
Why This Approval Matters
Stem cell transplantation has saved thousands of lives, but chronic graft-versus-host disease remains one of its greatest long-term challenges.
Tregzi is the first FDA-approved regulatory T cell-based immunotherapy, representing a new way of improving transplant outcomes. Instead of simply suppressing the immune system after transplant, the therapy is designed to help the immune system rebuild in a more balanced way from the beginning.
If longer-term follow-up confirms these early results, this approach could change the standard of care for many patients undergoing matched donor stem cell transplantation for blood cancers.
Questions to Ask Your Doctor
If you are preparing for a stem cell transplant, consider asking:
- Am I eligible for Tregzi?
- Do I have a matched donor?
- How does this therapy differ from a standard stem cell transplant?
- What are my risks for graft-versus-host disease?
- How will my recovery and follow-up care be monitored?
Reference
U.S. Food and Drug Administration. FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies. June 30, 2026.
